NRx Pharmaceuticals, Inc. (NRXP)

Market Cap	27.82M
Revenue (ttm)	n/a
Net Income (ttm)	-25.65M
Shares Out	10.70M
EPS (ttm)	-3.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,993
Open	2.570
Previous Close	2.580
Day's Range	2.531 - 2.690
52-Week Range	1.900 - 7.330
Beta	1.29
Analysts	Strong Buy
Price Target	43.00 (+1,553.85%)
Earnings Date	Aug 12, 2024

About NRXP

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track desi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: NRXP

Analyst Forecast

According to one analyst, the rating for NRXP stock is "Strong Buy" and the 12-month stock price forecast is $43.0.

Price Target

$43.0

(1,553.85% upside)

Analyst Consensus: Strong Buy